-- Safety update shows Phase 1 study unable to reach optimal therapeutic index for MM-310 due to continued observation of cumulative peripheral neuropathy -- -- Company expects to reduce workforce reflective of narrowed preclinical development pipeline; continues to prudently advance programs while
CAMBRIDGE, Mass. , March 6, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its fourth quarter and full year 2018 financial results for the period ended December 31, 2018 .
- Company to initiate corporate restructuring, including ~60% reduction in force and significant reduction in operating expenses; potential to extend runway into at least 2H 2022 to preserve ability to capture Ipsen milestones - - Has engaged external advisors to evaluate strategic alternatives - -
CAMBRIDGE, Mass. , Oct. 31, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its third quarter 2018 investor conference call and webcast at 8:30 am ET on Wednesday, November 7, 2018. The call will provide an update on Merrimack's
- MM-121 did not improve progression free survival (PFS) in patients with non-small cell lung cancer (NSCLC) - - Company to provide pipeline review update on third quarter financial results call, November 7, 2018 - CAMBRIDGE, Mass. , Oct. 19, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.
CAMBRIDGE, Mass. , Sept. 20, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has received a $5 million milestone payment from Shire, triggered by the sale of ONIVYDE in the first
CAMBRIDGE, Mass. , Sept. 6, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has completed enrollment in its ongoing SHERLOC study, a Phase 2 clinical trial evaluating its lead
- $18 million milestone payment received from Shire; Company continues to strengthen cash position from non-dilutive sources - - Two clinical readouts anticipated in 2018: randomized Phase 2 SHERLOC study of MM-121 in metastatic non-small cell lung cancer and Phase 1 study of MM-310 in solid tumors
CAMBRIDGE, Mass. , July 31, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its second quarter 2018 investor conference call and webcast at 8:30 am ET on Tuesday, August 7, 2018. The call will provide an update on Merrimack's recent
- Non-dilutive financing strengthens cash position - - Multiple clinical read-outs expected later this year - CAMBRIDGE, Mass. , July 2, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the